Cadus Pharmaceutical Corp. (KDUS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS)

KDUS 1.600

0.0%

Jul 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (460)	1/27/2001 10:06:21 PM
From: Tomato	Read Replies (2) of 1833

Question: If I recall correctly, you said sometime back that you felt that KDUS might be earning $4 or so per share by 2004 or 2005 from royalties from their patents (which was why you were long the stock as I recall). What I don't get is the mechanics of how this happens. From the 10-Q: On July 30, 1999, the Company sold its drug discovery assets to OSI Pharmaceuticals, Inc. ("OSI") and ceased its internal drug discovery operations and research efforts for collaborative partners. The Company expects to generate revenues in the future only if it is able to license its technologies. If the assets are sold, wouldn't that include patents? Or does the sale of assets to OSI include a royalty provision? Or would the royalties come via KDUS's interest in Axiom or Laurel Partners? Any clarification would be appreciated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next